Galapagos NV (NASDAQ:GLPG – Get Free Report)’s stock price hit a new 52-week low during trading on Wednesday . The company traded as low as $28.30 and last traded at $28.73, with a volume of 5527 shares changing hands. The stock had previously closed at $28.45.
Wall Street Analyst Weigh In
Several equities research analysts have weighed in on GLPG shares. Morgan Stanley reissued an “equal weight” rating and set a $38.00 price objective on shares of Galapagos in a research note on Monday, April 22nd. StockNews.com downgraded Galapagos from a “buy” rating to a “hold” rating in a research report on Monday, March 18th. Finally, Bank of America restated an “underperform” rating and issued a $31.00 price target (down from $41.00) on shares of Galapagos in a research report on Thursday, March 28th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $34.50.
Get Our Latest Analysis on GLPG
Galapagos Stock Performance
Institutional Trading of Galapagos
Several institutional investors and hedge funds have recently made changes to their positions in GLPG. GAMMA Investing LLC purchased a new position in Galapagos in the 4th quarter worth about $44,000. Quadrant Capital Group LLC boosted its holdings in shares of Galapagos by 18.1% in the fourth quarter. Quadrant Capital Group LLC now owns 1,706 shares of the biotechnology company’s stock valued at $69,000 after purchasing an additional 261 shares during the period. Tower Research Capital LLC TRC grew its stake in Galapagos by 2,317.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,934 shares of the biotechnology company’s stock worth $79,000 after purchasing an additional 1,854 shares in the last quarter. Signaturefd LLC increased its holdings in Galapagos by 78.6% during the 4th quarter. Signaturefd LLC now owns 1,970 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 867 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its position in Galapagos by 357.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,265 shares of the biotechnology company’s stock valued at $92,000 after purchasing an additional 1,770 shares in the last quarter. 32.46% of the stock is currently owned by institutional investors.
Galapagos Company Profile
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
Featured Stories
- Five stocks we like better than Galapagos
- Using the MarketBeat Dividend Yield Calculator
- AMD is Down 35%. Now is the Time to Buy the Dip
- Insider Trading – What You Need to Know
- Amazon Stands Tall: New Highs Are in Sight
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Chesapeake Energy Stock is The Energy Play, Earnings Confirm
Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.